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ECONOMIC EVALUATION STUDY

Measuring the Potential Impact of Combination HIV
Prevention in Sub-Saharan Africa
Amin Khademi, PhD, Sunanth Anand, MSc, and David Potts, MD

Abstract: A public health approach to combination HIV prevention is
advocated to contain the epidemic in sub-Saharan Africa. We explore
the implications of universal access to treatment along with HIV
education scale-up in the region. We develop an HIV transmission
model to investigate the impacts of universal access to treatment, as well
as an analytical framework to estimate the effects of HIV education
scale-up on the epidemic. We calibrate the model with data from South
Africa and simulate the impacts of universal access to treatment along
with HIV education scale-up on prevalence, incidence, and HIV-related
deaths over a course of 15 years. Our results show that the impact of
combined interventions is significantly larger than the summation of
individual intervention impacts (super-additive property). The combined strategy of universal access to treatment and HIV education scaleup decreases the incidence rate by 74% over the course of 15 years,
whereas universal access to treatment and HIV education scale up will
separately decrease that by 43% and 8%, respectively. Combination
HIV prevention could be notably effective in transforming HIV epidemic to a low-level endemicity. Our results suggest that in designing
effective combination prevention in sub-Saharan Africa, priorities
should be given to achieving universal access to treatment as quickly
as possible and improving compliance to condom use.
(Medicine 94(37):e1453)
Abbreviations: ART = antiretroviral therapy, STD = sexually
transmitted disease, WHO = World Health Organization.

INTRODUCTION

H

IV/AIDS is one of the world’s pressing infectious diseases.
More than 35 million people are infected with HIV and this
number is still increasing.1 The area hit hardest by the epidemic
is sub-Saharan Africa where more than 22 million are infected
and the primary route of infection is heterosexual.1 Significant
efforts have been carried out by sub-Saharan African nations, in
cooperation with developed nations, the World Health Organization (WHO), the pharmaceutical industry, and many private
charities to curb the epidemic. A public health approach to
combination HIV prevention is recently advocated to transform
HIV transmission from a pandemic to low-level endemicity.2
The purpose of this study is to develop a dynamic HIV
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transmission model to measure the impacts of a combined
HIV prevention program on HIV trends in sub-Saharan Africa.
In particular, we consider universal access to treatment (defined
as coverage of at least 80% of the population in need) combined
with HIV education scale-up.
HIV prevention programs have been quite successful in
sub-Saharan Africa. The availability of antiretroviral therapy
(ART), the only treatment option for chronic HIV, has substantially increased over the last decade in sub-Saharan Africa:
treatment coverage has increased from 3% in 2003 to 50% in
2013.3 Moreover, HIV education that is a key to every HIV
prevention program has been highly promoted and many
countries in the region have developed national policy on
HIV/AIDS education.4 For instance, the ABC strategy (abstinent, be faithful, use a condom) to HIV prevention decreased
the HIV infection rate in Uganda from 15% in 1991 to 5% in
mid-1990s.5 Partner reduction and fidelity has had a significant
impact on incidence reduction in several parts of the region. In
Cambodia where the prevention efforts reduced HIV incidence, the proportion of men who reported paying for sex
has declined.6 In Zambia, faith-based campaigns to promote
abstinence and monogamy among young people decreased the
HIV prevalence in young women during the 1990s.7 A decline
in HIV incidence in Kenya is reported to be associated with
behavioral changes.8 Similar trends are observed in Addis
Ababa, Ethiopia, and Dominican Republic.9
Modeling the impacts of ART on HIV progression in an
HIV-infected individual, as well as a population of susceptible
and infected individuals, has received a significant attention in
both resource-rich and resource-limited settings. In the patient
level, Perelson et al10 examined a model for the interaction of HIV
with CD4 cells and considered the effects of AZT on viral growth
and CD4 dynamics. Braithwaite et al11 developed a simulation
model for HIV progression in an infected individual and
examined alternative thresholds for ART initiation. Walensky
et al12 created a simulation model to inform HIV treatment
decisions regarding the optimal CD4 threshold in South Africa.
In the population level, researchers have developed models to
investigate the consequences of ART scale-up on the HIVinfected population.13–17 In particular, Granich et al13 developed
a mathematical model that predicted that HIV can be eliminated
in South Africa by implementing the test-and-treat strategy in 40
years with approximately $10 billion less cost than universal
access to treatment.
Despite significant research on modeling the impacts of
ART on HIV trends, the literature on modeling the potential
impacts of HIV education scale-up on HIV trends is scarce and
most attention is given to designing clinical studies to investigate the effects of behavioral change in the population on HIV
progression.18–21 Enns et al22 created a model to estimate the
effectiveness of changes in concurrent sexual partnerships in
reducing the spread of HIV in sub-Saharan Africa. Kretzschmar
and Morris23 investigated the impact of concurrent partnerships
on epidemic spread. Kessler et al24 estimated the reduction in
www.md-journal.com |
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HIV incidence in New York City due to behavioral changes via
simulation. However, the focus of these studies is on modeling
one of the benefits of HIV education at a time and they did not
model the simultaneous effect of various benefits of HIV
education. In this study, we develop an analytical framework
to estimate the effects of HIV education on HIV metrics such as
incidence, prevalence, and mortality. In particular, we consider
compliance to partner reduction and condom use and our
results shed light on the role compliance plays in curbing
the epidemic.

METHODS
In a broad view, we classify the population into 3 categories:
sexually active susceptible individuals (hereafter, susceptible
individuals), infected individuals not on treatment, and infected
individuals on treatment. Let XðtÞ, YðtÞ, and ZðtÞ denote the total
number of susceptible, nontreated infected, and treated infected
individuals, respectively. To be able to model viral loads (hence
infectivity), we classify infected individuals into 3 groups:
primary, chronic, and symptomatic stages of HIV infection.25
That is, Y1 ðtÞ, Y2 ðtÞ, and Y3 ðtÞ denote the number of untreated
infected individuals in primary, chronic, and symptomatic stage of
HIV at time t, respectively. Therefore, infectivity is highest in
primary infection, lower in chronic infection, and increases again
in symptomatic stage. We assume that HIV-infected individuals
spend 2 months in primary infection, 7.5 years in the chronic
stage, and 3.5 years in the symptomatic stage.25 Also, let Z1 ðtÞ,
Z2 ðtÞ, and Z3 ðtÞ, respectively, denote the number of treated
infected individuals in primary, chronic, and symptomatic stage
of HIV at time t. We use data available in the literature to estimate
the survival time of infected individuals after initiating treatment.25 At time t the total number of individuals who become
sexually active and join the susceptible population is denoted by
bðtÞ. Let IðtÞ and PðtÞ be the incidence and prevalence of the
disease at time t. We assume that the transmission is due to
heterosexual partnership. This assumption is mild in our setting
because concurrent sexual partnership is the key driver in HIV
epidemic in sub-Saharan Africa.26
Aligned with the literature, we consider an exponentially
decay function to incorporate the heterogeneity in the population. In particular, we use leaPðtÞ , where the transmission
rate takes value of l (transmission parameter) in the beginning
of the epidemic and decays exponentially with rate a times the
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prevalence.27 Therefore, we have
IðtÞ ¼ leaPðtÞ X ðtÞ

P3

i¼1 ðvi Yi ðtÞ þ

2 vi Zi ðtÞÞ

N ðtÞ

where vi denotes the infectivity of an infected individual in
category i per unit time, 2 captures the effect of treatment on
reducing the infectivity of an infected individual, and NðtÞ
denotes the total number of individuals in the population.
Infected individuals on treatment may stop using treatment
due to side effects of ART or they may develop resistant
mutations. In order to incorporate these phenomena, infected
individuals with rate g move from being on treatment to not on
treatment. The underlying assumption is that the health progression of infected individuals after stopping treatment or
developing resistant mutations is similar to untreated individuals (see Granich et al13 for this assumption). Figure 1 shows an
overview of the model and Table 1 provides a complete list of
parameters used in the model as well as their values. See
Appendix 1, http://links.lww.com/MD/A393, for more details
regarding the transmission model.
In our model, HIV education affects the epidemic by
changing the sexual behavior of individuals in 2 dimensions:
the expected number of partners that an individual establishes,
and the likelihood of using condoms. Although HIV education
has potentially other benefits such as stigma reduction and HIV
test rate increase, we considered the 2 abovementioned factors
because studies show that most benefit of HIV education is due
to a reduction in partner acquisition and an increase in the
frequency of condom use.8 Next, we show how HIV education
impacts incidence. The transmission parameter, l, can be
written as
l ¼ l0 c’
where c is the number of partners that a susceptible individual
establishes in a period, and w is the probability of infection in a
partnership.28 As mentioned earlier, education impacts both c
and w, that is, both of them are a function of education. Let
0  u  1 denote the proportion of individuals in the society
educated with sexually transmitted diseases (STD), where zero
shows that nobody is STD educated and one shows that all
individuals are STD educated. We consider the compliance of
individuals to partner acquisition reduction and condom use in

FIGURE 1. Model overview. See Appendix 1, http://links.lww.com/MD/A393 for details regarding the transmission model.
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TABLE 1. Model Parameters and Their Values
Parameter

Description

B
e50m
1=r1
1=r2
1=r3
1  eg
t1
t2
t3
1=s 1
1=s 2 þ 1=ðr2 þ t 2 Þ  1=r2
es 3 ð20 þ 1=r3  1=ðr3 þ t 3 ÞÞ

Rate of joining the sexually active population
Probability of a sexually active, HIV-negative individual surviving 50 yr or more
Mean duration of primary infection
Mean duration of chronic infection
Mean duration of symptomatic infection
Probability of interrupting treatment per year
Per capita treatment rate during primary infection
Per capita treatment rate during chronic infection (>350 cells/mL)
Per capita treatment rate during symptomatic infection (<350 cells/mL)
Mean duration of treatment in stage A1
Mean life-years gained through early treatment versus treatment at 350 cells/mL
Probability of gaining more than 20 yr of additional life, if treatment is initiated at 350
cells/mL
Transmission rate: primary infection
Transmission rate: chronic infection
Transmission rate: symptomatic infection
Reduction in infectivity due to treatment

v1
v2
v3
1 2

Value
582,000 yr–1
70%
2 mo
7.3 yr
3.5 yr
2%
0 yr1
0 yr1
1.0 yr1
2 months
6 yr
62%
0.51 yr1
0.11 yr1
0.15 yr1
90%

Values are based on Wagner and Blower.24

our model. Let #1 and #2 denote the compliance of an STDeducated individual to partner acquisition reduction and condom use, respectively. Note that #1 and #2 may depend on other
factors such as time and education level, but for ease of notation,
we drop any dependences. By assuming a linear relation, we
have
cðuÞ ¼ uð1  #1 pÞcð0Þ þ ð1  uÞcð0Þ
’ðuÞ ¼ uð1  #2 dÞ’ð0Þ þ ð1  uÞ’ð0Þ
where p is the reduction in number of partners due to education,
and d is the reduction in the probability of infection due to
condom use. Now suppose that we increase the level of education in the society and the new proportion of STD-educated
individuals is u 0  u. A similar calculation reveals that
cðu0 Þ ¼

1  #1 u 0 p
cðuÞ
1  #1 up

’ðu0 Þ ¼

1  #2 u0 d
’ðuÞ
1  #2 ud

Therefore, the effect of education
scale-up on incidence is
.
0
0
1 u p 1#2 u d
given by Iðu0 Þ ¼ 1#
IðuÞ.
1#1 up 1#2 ud
We used demographic and epidemiologic data from South
Africa to parameterize our model. Then, we calibrated the
transmission model by comparing the HIV prevalence generated by the model with the actual HIV prevalence observed in
South Africa from 1990 to 2000 because ART was insufficiently
available during that period.29 Pursuant to this goal, we set the
initial state of the epidemic in the model to that observed in
1990 in South Africa and change the heterogeneity factor, a, to
fit the curve.
We used the calibrated model to simulate the impacts of a
variety of intervention combinations on the epidemic. In particular, we simulated the impacts of HIV education scale-up and
Copyright
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universal access to treatment separately as well as a variety of
their combinations. For simulating universal access to treatment,
we started treating infected individuals as soon as they moved to
the symptomatic stage. We estimated the HIV education
parameters by using the data available in the literature. In
particular, we assumed that STD-educated individuals have
35% reduction in number of partners and their compliance to
partner reduction is 77%.30 We assumed that condom use will
decrease the likelihood of infection by 90% and the compliance of
STD-educated individuals to condom use is 59%.31,32 Because we
could not locate a comprehensive study on HIV literacy rate in
sub-Saharan Africa, we used the literacy rate as an indicator of
HIV literacy rate as they are strongly correlated.33 Therefore, we
assumed that the HIV literacy rate is 66%.34 We increased the
HIV literacy rate to 90% in the population and simulated its
impact on the epidemic. We also conducted several sensitivity
analyses to test the robustness of the results by changing the
values of model parameters.
Since implementing universal access to treatment and HIV
education scale-up will take time in practice, we assume that
their coverages increase logistically in time. That is, if we let
uðtÞ be the HIV literacy rate at time t and ū be our target for the
HIV literacy rate, we use the following formula:
uðtÞ ¼ u0 þ ðū  u0 Þ

ebðtt0 Þ
1 þ ebðtt0 Þ

where u0 is the initial literacy rate, t0 is the time at which the
logistic term reaches 0.5, and b determines the rate at which the
literacy rate increases. We set these parameters in the model such
that the target is reached within 2 years. A similar approach is
used for increasing the treatment coverage over time. Note that
because this is a modeling study, ethical approval is not necessary.

RESULTS
Figure 2 shows the results of the model calibration. It compares
the HIV prevalence generated by the model (solid line) with the
historical prevalence (dotted line) observed in South Africa
www.md-journal.com |
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FIGURE 2. Model calibration. It shows the result of the calibration
phase. We used demographic and epidemiologic data from South
Africa to parameterize our model. It compares the HIV prevalence
generated by the model (solid line) with the historical prevalence
(dotted line) observed in South Africa from 1990 to 2000.

from 1990 to 2000. We used the calibrated model to investigate
the impact of combination of various interventions on the
epidemic for 15 years. Figure 3 shows the results of the
simulation in terms of incidence rate and prevalence for HIV
education scale-up (compound line), universal access to treatment (dotted line), and HIV education scale-up along with
universal access to treatment (solid line).
Our results show that by just HIV education scale-up, the
epidemic growth slows down and the incidence rate slightly
drops. During the course of 15 years, the incidence rate changes
from 2.3% to 2.1%. By implementing universal access to
treatment, our results show that the incidence rate drops and
decreases over time which results in a decrease in prevalence. In
particular, the incidence rate changes from 2.3% to 1.3% and the
prevalence changes from 15.1% to 13.3%. More importantly,
our results show that HIV education scale-up combined with
universal access to treatment significantly decreases the incidence rate from 2.3% to 0.6% and prevalence decreases from
15.1% to 9.3% over a course of 15 years. This shows that the
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benefit of a combined strategy of universal access to treatment
and HIV education scale-up is greater than the summation of
their individual benefits, that is, it has super-additive property.
In particular, the combined strategy will decrease the incidence
rate by 74% over the course of 15 years, whereas universal
access to treatment and HIV education scale-up will separately
decrease that by 43% and 8%, respectively.
We observed a reduction in the cumulative HIV-related
deaths by implementing the interventions. Compared with HIV
education scale-up strategy, universal access to treatment
averted 7,596,439 deaths whereas universal access to treatment
along with HIV education scale-up averted 7,679,917 deaths in
the course of 15 years. This shows that the significant reduction
in HIV-related deaths is due to universal access to treatment.
We conducted a sensitivity analysis to test the robustness
of model results and to investigate the significance of each
parameter on model outcomes. We perturbed the model
parameters for the combined strategy of universal access to
treatment along with HIV education scale-up. Table 2 reports
the results of the HIV incidence rate reduction after 15 years
compared with the initial incidence rate, and the cumulative
number of HIV-related deaths averted compared with that in the
HIV education scale-up strategy. Our results show that by
considering the current reports on model parameters in the
literature, compliance to condom use is the most critical factor:
if it dropped to 30%, the incidence rate reduction would decline
to 60% (for the base case it is 74%), and if it increased to 90%,
the incidence rate reduction would increase to 87%. This insight
suggests that efforts in designing more effective HIV education
programs should be on promoting individuals’ compliance to
condom use.

DISCUSSION
HIV prevention programs that aim to stop the spread of the
disease have been relatively successful in reducing the incidence rate in sub-Saharan Africa during the past 2 decades.
Recently, more comprehensive prevention strategies are available due to scientific and epidemiological advances. In particular, combination prevention is highly advocated to achieve
maximum effect on curbing the epidemic in a specific setting.
In this study, we developed a dynamic HIV transmission model

FIGURE 3. Results of simulation. Panels (A) and (B) show the evolution of HIV incidence rate and prevalence under different strategies
over the course of 15 years, respectively. Our results show that by just implementing HIV education scale-up strategy (compound line), the
incidence rate over 15 years drops from 2.3% to 2.1%; thus prevalence keeps increasing. Implementing universal access to treatment
(dotted line) decreases the incidence rate from 2.3% to 1.3% in 15 years and consequently prevalence decreases from 15.1% to 13.3%
over this period. Universal access to treatment combined with HIV education scale-up significantly decreases the incidence rate from 2.3%
to 0.6% which results in a substantial prevalence drop of 6% over 15 years.
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TABLE 2. Sensitivity Analysis

Reduction in partner acquisition due to
education (%)
Reduction in transmission probability due
to condom use (%)
Compliance to partner reduction (%)
Compliance to condom use (%)

Low

Base

High

Incidence Rate
Reduction (%)

Number of
HIV Deaths Averted

10

35

70

(69; 74; 82)

(7,666,433; 7,679,917; 7,705,452)

85

90

99

(73, 74, 78)

(7,675,760; 7,679,917; 7,687,850)

30
30

77
59

90
90

(69, 74, 78)
(60, 74, 87)

(7,668,209; 7,679,917; 7,683,600)
(7,648,256; 7,679,917; 7,729,765)

We varied several assumptions regarding the model parameters to assess the robustness of model predictions. In particular, we focused on the
parameters of HIV education scale-up. For example, we varied the rate of reduction in partner acquisition, reduction in transmission probability,
compliance to partner reduction, and compliance to condom use. For each scenario, Table 2 reports the results for combined strategy of universal
access to treatment and HIV education scale-up. Our results show that by considering the current reports on model parameters in the literature,
compliance to condom use is the most critical factor: if it dropped to 30%, the incidence rate reduction would decline to 60% (for the base case it is
74%), and if it increased to 90%, the incidence rate reduction would increase to 87%. This insight suggests that efforts in designing more effective HIV
education programs should be on promoting individuals’ compliance to condom use.
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